MEDIUMLEGISLATION_STATE

CA AB1990: Pharmacy Law: advertising certain compounded medications used for obesity or weight management.

Published Jun 29, 2026Source: State Legislation (LegiScan)View original

Summary

This California bill regulates the advertising of compounded medications used for obesity or weight management, which directly affects peptide-based GLP-1 receptor agonists like compounded semaglutide and tirzepatide. While not banning the substances, it introduces restrictions on how compounding pharmacies and vendors can market these products in California. The bill is still progressing through committee and is not yet law.

AI Analysis

Key Changes

•Establishes advertising restrictions for compounded medications used in obesity/weight management
•Targets compounding pharmacies marketing weight-loss peptide therapies
•Bill passed committee (Ayes 7, Noes 3) and re-referred to Judiciary Committee on June 29
•Likely to require disclosures or limit claims made in advertisements for compounded weight-management drugs

Affected Peptides

semaglutidetirzepatidecompounded GLP-1 agonists

Affected States

Action Required

Vendors and compounding pharmacies operating in or advertising to California should monitor this bill's progress and review their marketing materials for compounded weight-management peptides to ensure future compliance with advertising restrictions.

Full Document Text

Pharmacy Law: advertising certain compounded medications used for obesity or weight management. Last action: From committee: Do pass and re-refer to Com. on JUD. (Ayes 7. Noes 3.) (June 29). Re-referred to Com. on JUD. Status:

Alert created: Jun 30, 2026, 3:48 PM